SPY002 for colitis, ulcerative

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 27 May 2025: Trial started, NCT07012395
  2. 10 Jun 2025: Trial registered, NCT07012395
  3. 8 Jun 2026: Trial started, NCT07652294
  4. 17 Jun 2026: Trial registered, NCT07652294

The trials

NCT07012395: A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

State
Under way
Phase
Phase 2
People
645 planned
Started
27 May 2025
Primary completion
Jun 2027
Arms
Intervention Specific Appendix - SPY002: Part A, Intervention Specific Appendix - SPY002 Dosing Regimen 1: Part B, Intervention Specific Appendix - SPY002 Dosing Regimen 2: Part B
Results
None posted
  1. 27 May 2025: Trial started
  2. 10 Jun 2025: Trial registered

NCT07652294: Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

State
Under way
Phase
Phase 2
People
645 planned
Started
8 Jun 2026
Primary completion
2 Mar 2029
Arms
SPY002 Dosing Regimen 1, SPY002 Dosing Regimen 2, SPY002 Dosing Regimen 3
Results
None posted
  1. 8 Jun 2026: Trial started
  2. 17 Jun 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.